Harris James Associates Compiled News: Anthera Pharmaceuticals Successfully Completes Interim
Biomarker Analysis
Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third
Safety Review of Varespladib Methyl
James...
More
Harris James Associates Compiled News: Anthera Pharmaceuticals Successfully Completes Interim
Biomarker Analysis
Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third
Safety Review of Varespladib Methyl
James Harris Associates mission is to embrace our client s goals as our own and to work as an extension of
the client organization to reach our common objective.
We know that we will be successful only if we make
our clients more successful.
VISTA-16 Study to Continue Global Enrollment
HAYWARD, Calif.
, April 18, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH), a
biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today
announced that enrollment in the Phase 3 VISTA-16 study of varespladib in Acute Coronary Syndromes
(ACS) will continue based on the positive outcome of an interim biomarker analysis and review of available
patient safety data.
An independent statistician c
Less